Zepbound
Payments companies reported to CMS as associated with Zepbound. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zepbound, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zepbound
These are the largest totals companies reported as associated with Zepbound. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ethan Lazarus | Denver, CO | Family Medicine | $163,901.40 |
| Jeffrey Sicat | Glen Allen, VA | Endocrinology, Diabetes & Metabolism | $160,633.11 |
| Dana Portenier | Durham, NC | Surgery | $159,979.54 |
| Holly Lofton | New York, NY | Obesity Medicine (Preventive Medicine) | $159,721.19 |
| Jesse Richards | Tulsa, OK | Internal Medicine | $158,778.56 |
| Arash Nayeri | Los Angeles, CA | Cardiovascular Disease | $157,921.54 |
| Ken Fujioka | San Diego, CA | Endocrinology, Diabetes & Metabolism | $156,748.07 |
| Bradley Eilerman | Florence, KY | Endocrinology, Diabetes & Metabolism | $156,050.26 |
| Donna Ryan | Baton Rouge, LA | Internal Medicine | $154,448.34 |
| Carolynn Francavilla Brown | Lakewood, CO | Family Medicine | $152,553.83 |
Prescribed Zepbound?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.